Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Strategy

AbbVie's plan B

What AbbVie really needs from Shire besides inversion benefits

July 21, 2014 7:00 AM UTC

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty pharma's rare disease portfolio and pipeline, along with its ADHD franchise, could help fill a potential revenue gap.

AbbVie's fifth offer since May, when the pharma started to privately court the Irish company, values Shire at £31.4 billion ($54.5 billion) and is a 35% premium to the biotech's first bid of £23.6 billion ($39.9 billion). The deal is 46% cash and 54% stock...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article